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Abstract
Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-
bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is
associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade
inflammation marker reflecting on disease severity. The aim of this prospective observational study was to
determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/
Charlson Comorbidity Index Score, and mortality.
Methods: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month
period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was
measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion
by their unique civil registry number and using Danish registries to determine admission times, readmissions,
International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to
determine suPAR’s association with these endpoints.
Results: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml
in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with
readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and
Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those
with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities.
Conclusions: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous
cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in
prognostic algorithms.
Introduction
At acute medical units, the crucial decision is whether
to admit or discharge a patient. Currently, this decision
is based on a clinical examination of the patient and on
various diagnostic tests. A reliable prognostic algorithm
can aid in deciding whether to run a diagnostic panel,
as well as whether to discharge or admit a patient. A
new biomarker that may be useful in prognostic algo-
rithms is soluble urokinase plasminogen activator recep-
tor (suPAR). SuPAR is the soluble form of urokinase
plasminogen activator receptor (uPAR), a receptor
mainly expressed on various immunologically active
cells such as macrophages, neutrophils, and activated T
lymphocytes, as well as on endothelial cells [1]. uPAR is
involved in plasminogen activation, cell adhesion and
migration, all central aspects of inflammatory processes,
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and it is upregulated in response to immune activation
[2]. Plasma levels of suPAR have been shown to be a
risk marker in patients with various infectious diseases
[3-5] and in the intensive care settings [6-8]. High levels
of suPAR are associated with increased risk of early
mortality [9] and the suPAR level is thought to reflect
disease severity [6].
The Charlson Comorbidity Index Score (Charlson
Score) is calculated on the basis of patient diagnoses
coded according to the International Classification of
Diseases, 10th Edition (ICD-10), which are listed upon
discharge from the hospital. A weighted score is assigned
to each of 17 comorbidity groups based on the relative
risk of 10-year mortality. The cumulative score of these
17 groups has been validated as a prognostic indicator in
large patient groups, with higher scores indicating a
higher risk of dying. In a recent study by Christensen et
al., the Charlson Score, along with other administrative
parameters, predicted one-year mortality with similar
precision as the Simplified Acute Physiology Score (SAPS
II) and Acute Physciology and Chronic Health Evaluation
(APACHE) [10]. To our knowledge, a possible associa-
tion between suPAR and the Charlson Score has not
been investigated previously.
The association between increased plasma suPAR and
increased mortality is documented in patients with HIV or
sepsis, and in people from the general population
[4,8,11,12], but not in a more diverse patient population.
The object of the present study was to evaluate suPAR as
a risk marker in a diverse population of medical patients
admitted at an acute medical unit, and to determine
whether suPAR correlates with the Charlson Score, which




The Danish health care system provides treatment paid
for by taxes for primary care in hospital as well as
homecare services; these services are free of charge to
all Danish citizens. Furthermore, the hospitals are
obliged to provide information about all admissions to
the National Patient Registry. The information includes
the primary cause of admission and all comorbid dis-
eases, registered using ICD-10. All citizens of Denmark
have a unique civil registry number that makes it possi-
ble to follow them in various national registers.
Study population
Patients admitted to the Acute Medical Unit at Hvidovre
University Hospital between 4 August and 4 October
2010 were eligible for entry. Patients were included ran-
domly. A triage unit ensured that only medical patients
were admitted to the Acute Medical Unit. Exclusion
criteria were children under 18 years and patients with
no medical condition admitted solely because of acute
drug or alcohol intoxication. All included patients gave
written informed consent, and the study was approved by
the Science Ethics Committee of Copenhagen (protocol
no. H-2-2010-031). Patients were followed-up for three
months after inclusion using their unique civil registry
number. Information about the patients’ admissions and
ICD-10 diagnoses were extracted from the National
Patient Registry. Patients’ baseline diagnoses are the main
ICD-10 diagnosis from the admission in which they were
recruited. This diagnosis reflects what a patient was
admitted for, but it is not necessarily the most important
diagnosis. Baseline diagnoses were grouped according to
ICD-10 chapters into 6 groups with a 7th group (‘Other’)
composed of the 12 ICD-10 chapters with the fewest
patients (4 % or less of the total population each). Data
on mortality were extracted from the Danish Civil
Registry.
Sample handling
A peripheral venous blood sample was drawn within 24
hours of admission in a standard 4 mL K3 EDTA tube
(Cen-Med, East Brunswick, NJ, USA) and centrifuged at
3,000 × g for 10 minutes. After centrifugation, EDTA
plasma was transferred to a cryotube and stored at −20°C
until the plasma suPAR concentration was measured.
Blood samples stood at room temperature for up to
16 hours before centrifugation and freezing, but this has
previously been shown not to affect the plasma suPAR
concentration [13].
SuPAR measurement
SuPAR was measured using a commercially available
sandwich ELISA-kit (ViroGates A/S, Birkerød, Denmark)
according to the manufacturer’s instructions. Briefly,
plasma samples and standards with known suPAR con-
centrations were added to anti-suPAR-coated microtiter
plates and incubated in dilution buffer containing a
horseradish peroxidase-conjugated secondary antibody
for one hour. After washing to remove any unbound sec-
ondary antibody, 3,3’,5,5’-tetramethylbenzidine substrate
was added, and a color reaction developed for 20 min-
utes. The color reaction was terminated by the addition
of a sulfuric acid stop-solution. The plate was read at
450 nm with wavelength correction at 650 nm. The opti-
cal densities of the standards with known concentrations
were used to calculate the concentrations of the plasma
samples by creating a standard curve. The ELISA-kit
manufacturer provided the quantification software. All
samples were measured in duplicate, and the mean
suPAR concentration of the two measurements was used
for analysis. The variance between the two measurements
was generally low (mean 2.6%, range 0.0 to 12.4%), and
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only three samples had a variance >10%. None of these
samples were excluded, because all three had a low con-
centration of suPAR (<7.0 ng/mL), and thus low variance
in absolute values.
Other biomarkers
Plasma concentrations of CRP, creatinine, alanine amino-
transferase (ALAT), and albumin and blood concentra-
tions of hemoglobin and leucocytes are routine blood
analyses carried out upon admission to Hvidovre Univer-
sity Hospital. Creatinine, CRP, albumin, and ALAT con-
centrations were measured in blood samples drawn in
4 mL tubes with gel and lithium-heparin using a COBAS
6000 analyzer (Roche Diagnostics, Mannheim, Germany).
Blood leucocyte counts and hemoglobin concentrations
were measured in blood samples drawn in 4 mL K3EDTA
tubes using a Sysmex analyzer (Sysmex XE-5000, Kobe,
Japan). Two to five results were missing for each biomar-
ker due to hemolysis or lost samples.
Charlson Comorbidity Index
We used a SAS macro to calculate the Charlson Score
based on the patients’ ICD-10 diagnoses from the Danish
Patient Registry (for details, see [14]). Only one patient
had >4 points, and he was manually recoded to the score
4+ along with the patients who scored 4. For in-depth
analysis of suPAR’s association with the Charlson Score,
the original 17 comorbidity groups were collapsed into
seven. Groups 1 to 4 (originally named ‘myocardial
infarction,’ ‘congestive heart failure,’ ‘peripheral vascular
disease,’ and ‘cerebrovascular disease’) were collapsed
into ‘cardiovascular disease.’ Similarly, groups 9 and 15
(‘mild liver disease’ and ‘moderate/severe liver disease’)
were collapsed into ‘liver disease.’ Groups 10 and 11
(‘diabetes without complications’ and ‘diabetes with com-
plications’) were collapsed into ‘diabetes.’ Groups 14 and
16 (‘cancer’ and ‘metastatic carcinoma’) were collapsed
into ‘cancer.’ Finally, groups 5 to 7 (‘dementia,’ ‘chronic
pulmonary disease,’ and ‘rheumatic disease’) remained
the same, while groups 8 (’peptic ulcer disease’), 12
(‘paraplegia and hemiplegia’), 13 (‘renal disease’), and 17
(‘HIV/AIDS’) were discarded, because there were fewer
than five patients in each group.
Statistical analysis
The association between suPAR and categorical variables
was tested with a standard nonparametric one-way analy-
sis (Kruskal-Wallis test), and the correlation between
suPAR and the other biomarkers was tested with a Pear-
son correlation analysis. To study the adjusted effect of
suPAR on mortality and readmission, we used Cox
regression survival analysis with time to death and time
to readmittance, respectively, as time variables, and death
and readmittance, respectively, as censoring variables.
When studying time to readmission, a competing risk
model was used, and the patients were censored if they
died within 30 days from discharge. The mean suPAR
levels in the various modified Charlson groups were com-
pared to the Charlson Score = 0 group with a t-test for
equal or nonequal variances where appropriate. When
studying the admission time, we used standard linear
regression, where the 16 patients who died in hospital
(and thus had a falsely short admission) were censored.
The P values listed with the cumulative incidence plots
are from a Cox regression survival analysis as above, but
with the suPAR tertile or Charlson Score alone as the
explanatory variable. We used the SAS 9.2 package (SAS
Institute, Cary, NC, USA) for statistical analysis. The
cumulative incidence plots were compiled with the SPSS
12.0 package (IBM, Armonk, NY, USA), and the scatter-
plot was compiled with GraphPad Prism 5.04 (GraphPad
Software, San Diego, CA, USA).
Results
Baseline data
During the two month inclusion period, 569 patients were
enrolled. Of these, 20 had missing blood samples, two
withdrew consent, and four patients emigrated during fol-
low-up, leaving 543 patients for the final analysis. The
patients’ baseline characteristics are listed in Table 1.
There were 46.4% men, and the median age was 68.8
years. The median suPAR level was 4.28 ng/ml (range 0.99
to 25.10 ng/ml), and there was no association between sex
and plasma suPAR concentration (P = 0.53). See Figure 1
for distribution of individual suPAR values. As shown in
Table 1, more than half of the patients scored 0 on the
Charlson Score, while five patients scored 4 or more. In
total, there were 219 different baseline ICD-10 diagnoses
when not grouped.
In all, 1,072 patients were admitted to the Acute Medi-
cal Unit during the two-month study period, and thus
529 (49 %) were not included in the study. Analysis of
anonymized data showed that these patients had a med-
ian age of 79.9 years versus 68.8 years for the study popu-
lation. Of the patients not included in the study, 41.6 %
were men while 46.4 % of the study population were
men. A total of 59.0 % had a Charlson Score of 0, 28.9 %
had a Charlson Score of 1, 8.51 % had a Charlson Score
of 2, 2.08 % had a Charlson Score of 3, and 1.51 % had
Charlson Score of 4+ (compare with Table 1).
Correlation between suPAR and other biomarkers
Pearson correlation analysis between suPAR and the
standard biomarkers taken at admission showed a signif-
icant and positive correlation between suPAR and CRP
(r = 0.28, P < 0.0001), creatinine (r = 0.25, P < 0.0001),
ALAT (r = 0.13, P = 0.0025) as well as leukocyte cell
count (r = 0.16, P < 0.0001). In contrast, hemoglobin
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and albumin showed a significant negative correlation to
suPAR (r = -0.26, P < 0.0001 and r = -0.50, P < 0.0001,
respectively).
Association of SuPAR with endpoints
SuPAR showed a positive association with age as well as
Charlson Score (both P < 0.0001, Table 2). A high
suPAR upon admission was associated with increased
length of hospital stay (P < 0.0001, Table 2).
With regard to readmission, no association between
baseline suPAR and readmission within 30 days was
observed (Table 2 and Figure 2a). A higher Charlson
Score was moderately associated with readmission
(Figure 2d), and when adjusted for sex and age, the
Hazard Ratio (HR) was 1.37 per 1 point increase in the
Charlson Score, P = 0.03.
High baseline suPAR and a Charlson score of 1 or more
was associated with increased 30-day (Figure 2b and 2e)
and 90-day (Figure 2c and 2f) mortality. The mortality risk
in the highest suPAR tertile was roughly similar to the
mortality risk when having a Charlson Score of 1 or more.
Baseline suPAR among 30-day (from admission) survivors
was 4.97 ng/ml compared to 7.31 ng/ml among those who
died (n = 27). Similarly, suPAR was higher in those who
died within 90 days (n = 48, 7.29 ng/ml) compared to
those who survived over the same period of time (4.87 ng/
ml). Furthermore, to determine whether suPAR was asso-
ciated with mortality among patients who were quickly
discharged, we carried out a subgroup analysis of patients
who were discharged within 48 hours of arrival at the hos-
pital (n = 289, 53%). Of these 289 patients, 12 were regis-
tered as dead 90 days after admission. Patients who died
during the 90 days of follow-up had significantly higher
suPAR (6.16 ng/ml) compared to 90-day survivors (4.15
ng/ml, P = 0.003). Similarly, the 16 patients who died dur-
ing admission had a higher suPAR (6.92 ng/ml) compared
to the 527 who either survived their admission or the
entire follow-up period (5.03 ng/ml, P = 0.0008).
Cox regression analyses
To model the association between suPAR and outcomes
while adjusting for confounders, we carried out Cox
Table 1 Baseline characteristics of the study cohort (n = 543).
Variable (unit) N Median or percent 2.5th Percentile 97.5th Percentile
Age (years) 543 68.8 24.2 92.7
Sex
Male 252 46.4 % - -
Female 291 53.6 % - -
Baseline diagnosis
Symptoms, signs or for observationa 126 23.2 % - -
Respiratory disease 112 20.6 % - -
Cardiovascular disease 88 16.2 % - -
Endocrine disease 43 7.9 % - -
Infectious diseaseb 36 6.6 % - -
Hematological disease 26 4.8 % - -
Other 112 20.6 % - -
Charlson Score
0 342 63.0 % - -
1 152 28.0 % - -
2 35 6.45 % - -
3 9 1.66 % - -
4+ 5 0.92 % - -
SuPAR (ng/ml) 543 4.28 1.81 13.6
Creatinine (μmol/l) 541 76.0 42.0 215
CRP (mg/l) 540 8.00 1.00 286
Leukocytes (109/l) 539 8.30 3.60 22.9
ALAT (U/l) 541 22.0 8.00 120
Albumin (g/l) 538 35.0 22.0 43.0
Hemoglobin (mmol/l) 541 7.90 5.00 9.90
aICD-10 Chapter XVIII diagnoses (R00-R99) and Chapter XXI diagnoses (Z00-Z99) collapsed; bICD-10 Chapter I diagnoses (A00-B99). Some values were missing for
biomarkers other than suPAR (samples failed because of hemolysis or because they were lost).
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regression analyses. When adjusting for age and sex, the
HR mortality estimate for each 1 ng/ml increase in
suPAR was 1.14 and 1.15 for 30- and 90-day mortality,
respectively (both P < 0.001). The HR of suPAR
remained significant after further adjustment for C-reac-
tive protein (CRP) (1.11 and 1.13 for 30- and 90-day
mortality, respectively) and the Charlson Score (1.10
and 1.11 for 30- and 90-day mortality, respectively)
(Table 3).
SuPAR in various Charlson groups
To further characterize the interaction between suPAR
and the Charlson Score, we calculated mean suPAR
values for all modified Charlson groups and compared
them to those with a Charlson Score of zero (Table 4).
Cancer, liver disease, diabetes, and cardiovascular disease
appeared to increase suPAR, while dementia and chronic
pulmonary disease (CPD) did not. Patients in the rheu-
matic disease group tended to have a higher suPAR, but
the difference was not significant.
To investigate the association between suPAR and
admission time, we carried out a linear regression of
admission time on age, sex, Charlson Score, and suPAR.
The SuPAR beta-value was 0.45 (P < 0.0001). In other
words, a 1 ng/ml increase in suPAR on average increased
the admission length by 0.45 days when adjusting for age,
sex, and Charlson Score.
Discussion
SuPAR as a potential disease severity marker
The association between increased suPAR and mortal-
ity has been extensively documented [7]. However,
most of the studies were confined to healthy subjects
[12] or subjects with well-defined illnesses, such as
tuberculosis [3] or HIV [15]. In this study, we aimed
to confirm suPAR’s association with mortality in a
more heterogeneous cohort, but also to investigate if
suPAR is a disease severity marker in a broader sense
through association with comorbidity burden (Charl-
son Score), admission length and readmission rates.
We found that suPAR showed a dose-response rela-
tionship with the Charlson Score, was strongly
Figure 1 Scatterplot showing the distribution of individual
suPAR values among those who died within 90 days and those
who survived for 90 days. Horizontal lines are the mean suPAR
values (4.87 ng/ml for survivors and 7.29 ng/ml for non-survivors).
Table 2 Mean suPAR (ng/ml) values in the various
groups.
Variable N Mean SD P
Age
18 to 50 years 114 3.66 2.28
50 to 70 years 167 5.05 3.61
More than 70 years 262 5.72 2.85 <0.0001
Sex
Male 252 5.14 3.14
Female 291 5.04 3.07 0.53
Admission time
0 days 98 3.72 1.82
1 day 189 4.50 2.57
2 to 7 days 159 5.53 2.59
8 days or more 81 7.06 4.83 <0.0001
Charlson Score
0 342 4.70 2.84
1 152 5.15 3.11
2 35 7.24 3.85
3 9 8.00 3.51
4 5 8.77 2.67 <0.0001
Readmitted
No 432 5.03 3.14
Yes 111 5.31 2.96 0.24
Table 2 Mean suPAR (ng/ml) values in the various
groups. (Continued)
Died within 30 days
No 516 4.97 3.01
Yes 27 7.31 3.89 0.0002
Died within 90 days
No 495 4.87 2.96
Yes 48 7.29 3.65 <0.0001
P values calculated with the Kruskal-Wallis test. SD indicates standard
deviation.
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associated with 30- and 90-day mortality, even when
adjusting for age, sex, Charlson Score and CRP, but
not associated with readmission rates. Given that the
Charlson Score is moderately associated with readmis-
sion (HR 1.37) and strongly associated with suPAR,
the lack of association between suPAR and readmis-
sions is somewhat surprising. Taken together, the asso-
ciation with higher mortality, longer admissions, and
higher comorbidity burden suggest that suPAR actually
reflects general disease severity.
SuPAR’s correlation with other biomarkers and the
modified Charlson groups
We found a significant positive correlation between
suPAR and CRP, creatinine, ALAT, and leukocytes while
there was a significant negative correlation between
suPAR, hemoglobin, and albumin. These associations
seem to support earlier studies. Elucidating on the kinetic
relation of the pathophysiology within these associations is
beyond the design of this study.
Both CRP and suPAR rise as part of an acute phase
response, but CRP is produced by hepatocytes [16]
whereas suPAR is produced peripherally mainly by leuko-
cytes and activated endothelium [1], which may explain
the positive association with leukocyte counts. Regarding
the inverse relationship with albumin and hemoglobin,
we interpret this as responses to chronic disease, for
example, advanced cancer: it causes cachexia and malnu-
trition (low hemoglobin and albumin) as well as a sys-
temic inflammation (high suPAR). There may be more
direct signaling pathways involved, but our design makes
it impossible to elucidate this further.
Figure 2 Cumulative incidence plots of readmissions and 30- and 90-day mortality. (a) Readmissions (P = 0.67), (b) 30-day mortality (P =
0.018), and (c) 90-day mortality (P = 0.0003) according to suPAR tertiles (n = 181 in each tertile). (d) Readmissions (P = 0.02), (e) 30-day mortality
(P = 0.002), and (f) 90-day mortality (P < 0.0001) according to a Charlson Score of zero (n = 342) or more than zero (n = 201).
Table 3 Hazard ratio for the listed outcomes per 1 ng/ml increase in suPAR when adjusting for age, sex, CRP, and
Charlson Score.
Adjustments Readmitted within 30 days Died within 30 days Died within 90 days
Age and sex 1.01 (0.95 to 1.07) 1.14 (1.06 to 1.23) 1.15 (1.08 to 1.22)
Age, sex, and CRP 1.02 (0.96 to 1.08) 1.11 (1.02 to 1.20) 1.13 (1.06 to .20)
Age, sex, and Charlson Score 0.99 (0.93 to 1.06) 1.10 (1.01 to 1.20) 1.11 (1.04 to 1.19)
95% confidence intervals in parentheses.
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Regarding the nature of the association with creatinine,
this is in agreement with Koch et al. who reported a simi-
lar correlation [6]. Also, there are reports that suPAR
may even cause the kidney disease, focal segmental glo-
merulosclerosis (FSGS). Wei and coworkes recently
showed that suPAR can enter the kidney glomerulus and
bind and activate the b3 integrin, one of the major pro-
teins anchoring podocytes to the glomerular basement
membrane, and that increased plasma levels of suPAR
lead to increased b3 integrin activation resulting in podo-
cyte dysfunction and proteinuria [17]. However, none of
the patients in this study were suffering from glomerular
disease and it is currently unknown if suPAR has an
active role in disease outside FSGS. Two earlier studies
found a strong connection between high suPAR and
decreased liver biosynthesis and cirrhosis [6,18], and the
association between ALAT and suPAR may support
these findings: also, patients in the Charlson group ‘Liver
disease’ had a mean suPAR of 11.8 ng/ml, the highest
mean value among the groups. If suPAR does not play an
active role in disease outside FSGS, it is likely that the
suPAR level reflects a conglomerate of negative biological
processes such as increased inflammation and fibrosis,
organ dysfunction and decreased organ biosynthesis.
SuPAR–a true prognostic marker?
The Charlson Score is known to perform well when pre-
dicting mortality [10], but requires diagnostic informa-
tion not always available upon admission, although this
may be the case for more chronic patients. Based on
adjusted analysis, suPAR levels appear to add informa-
tion about disease severity that cannot be explained by
the patient’s sex, age, and diagnoses alone. However, as
it also clear that interpretation of lone suPAR values is
very difficult (see Figure 1), we propose that suPAR may
be valuable as an addition to a prognostic model.
Because of this population’s heterogeneity and small
size, we cannot make sound suggestions for actual cut-
off values. Based on our results, such a prognostic
model should include age, sex, suPAR, and, ideally,
Charlson Score. A large prospective intervention trial is
needed to evaluate the performance of such a model in
actual clinical decision making, for example, whether to
admit a patient or not.
Limitations of the study
We included half the total number of patients admitted
to the Acute Medical Unit during the two month study
period. Gaps in the inclusion on Fridays and Saturdays
account for a fair proportion of these as patients. We
did not include patients on Fridays and Saturdays as the
protocol stated that plasma had to be separated from
blood within 24 hours, a job that was carried out by a
laboratory technician working on weekdays. Also, a
large proportion of the patients met exclusion criteria or
was unable to understand or sign the consent form in
an ethical manner. Less than one patient per day refused
to participate. According to an analysis of the unin-
cluded patients, the study population was 11.1 years
younger, but had a similar distribution of Charlson
Scores and sex as the unincluded patients. There was a
potential bias towards exclusion of the oldest and most
ill, as these patients were not always able to sign or
understand the consent form. If this were to change our
results, we expect that the associations found would be
similar, but with greater power as there would probably
be more fatality cases.
The validity of using ICD-10 codes from the Danish
Patient Registry for calculating the Charlson Score has
been documented in a large Danish cohort by Thygesen et
al. who found an overall positive predictive value (PPV) of
98% for the Charlson groups [19]. However, although the
diagnoses from the National Patient Registry are validated
for calculating the Charlson Score with a high PPV, they
are more inaccurate individually. This is because the
Charlson Score only incorporates more serious conditions
which are more likely to be coded correctly, and affiliated
diagnoses are grouped together in the Charlson groups
(for example, diabetes with complications), rendering dis-
crimination between these superfluous. Moreover, sub-
group analysis based on ICD-10 diagnoses would require
that we choose a main diagnosis among others based on
clinical experience; the Charlson Score does this automati-
cally, and thus the results are more reproducible. Another
limitation of the study was that we did not have sufficient
data to calculate SAPS, Sequential Organ Failure Assess-
ment (SOFA) or APACHE scores. Previous studies have
shown that Charlson Score has similar prognostic value,
and the association between comorbidites and suPAR was















N 342 50 10 81 6 54 8 17
SuPAR
(SD)




P 0.0081 0.85 0.47 0.28 0.0013 0.046 <0.0001
P value is for a t-test of the group compared to those not in a group. SD, standard deviation.
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the main purpose of this work. In an earlier study, suPAR
and age performed similarly to these physiologic scoring
systems in a cohort of 151 systemic inflammatory response
syndrome (SIRS) patients [20].
Conclusions
We found that plasma suPAR concentrations in a het-
erogeneous cohort of patients with various diseases are
not associated with readmission rates, but they are
strongly associated with admission time, as well as mor-
tality and the Charlson Comorbidity Index Score. Hence
suPAR is not only associated with increased mortality,
but it is a marker of overall disease severity.
Key messages
• suPAR is associated not only with mortality, but
also with admission time and the Charlson Comor-
bidity Index Score.
• suPAR is therefore a marker of disease severity in
general.
• The findings apply to a diverse patient population.
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